Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Pro Medicus Limited ( (AU:PME) ) is now available.
Pro Medicus’ U.S. subsidiary Visage Imaging has secured two five-year contract renewals worth a minimum of A$40 million, underscoring the strength of its Visage 7 enterprise imaging platform in major U.S. healthcare markets. The company renewed a A$31 million deal with MedStar Health for its full Visage 7 suite, including the addition of a cardiology imaging module, reinforcing its position in cloud-based imaging for large integrated health systems.
A separate A$9 million, five-year renewal with New York-based outpatient radiology provider Zwanger-Pesiri marks the client’s third contract term, highlighting long-term customer retention and perceived financial and clinical value of the platform. Both agreements are transaction-based with higher per-transaction fees and potential upside, supporting recurring revenue growth and enhancing Pro Medicus’ competitive standing in the U.S. radiology and cardiology imaging market.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$147.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited is an Australian healthcare informatics company that provides medical imaging software and services to hospitals, imaging centres and healthcare groups worldwide. Through its Visage 7 suite, the company delivers ultra-fast, scalable enterprise imaging solutions, including RIS, PACS, AI and e-health products deployable across public and private cloud environments.
YTD Price Performance: -39.75%
Average Trading Volume: 388,453
Technical Sentiment Signal: Hold
Current Market Cap: A$13.86B
Learn more about PME stock on TipRanks’ Stock Analysis page.